Key Findings
Nurix Therapeutics has reported new and updated clinical data from its ongoing NX-5948-301 Phase 1a/1b study, demonstrating durable responses and a favorable tolerability profile for bexobrutideg (NX-5948), an oral BTK degrader, in patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). The updated Phase 1a results revealed a median progression-free survival (PFS) of 22.1 months and an impressive objective response rate (ORR) of 83%.
Technical / Clinical Details
Bexobrutideg utilizes Nurix’s proprietary PROTAC® (Proteolysis-Targeting Chimera) technology to induce the degradation of the Bruton’s tyrosine kinase (BTK) protein, rather than merely inhibiting its activity like conventional BTK inhibitors. This mechanism offers a distinct advantage, particularly in patients who have developed resistance to existing BTK inhibitors. The Phase 1a study, a dose-escalation phase with an undisclosed number of patients, evaluated the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of bexobrutideg. The 83% ORR and 22.1-month median PFS are significant outcomes for a patient population with limited treatment options, underscoring the potent anti-cancer activity of this investigational agent. Furthermore, the favorable tolerability profile, with a low incidence of severe adverse events, enhances the drug’s potential for broad clinical utility.
Background & Context
CLL/SLL are common types of leukemia and lymphoma, where BTK inhibitors have become a cornerstone of therapy. However, a substantial number of patients either do not respond to initial BTK inhibitor treatment or develop resistance over time, leading to a critical unmet medical need. PROTAC technology represents a novel therapeutic modality that harnesses the cell’s ubiquitin-proteasome system to selectively degrade target proteins. This approach holds significant promise for overcoming drug resistance mechanisms seen with traditional inhibitors, making it one of the most exciting areas in modern drug discovery. Nurix’s success with bexobrutideg provides compelling clinical validation for the PROTAC platform in hematologic malignancies.
Strategic Significance & Outlook
The encouraging Phase 1a data for bexobrutideg provides a strong foundation for its continued development in Phase 1b and subsequent larger-scale clinical trials. Nurix Therapeutics aims to establish bexobrutideg as a leading treatment option for CLL/SLL, especially for patients who have exhausted other BTK inhibitor therapies. If these promising early results are replicated in later stages, bexobrutideg could significantly impact the treatment landscape for relapsed/refractory CLL/SLL, offering a new lease on life for many patients. Investors and clinicians will be closely watching the further progress of this PROTAC-based therapy, as it embodies the future direction of precision oncology.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments